RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCI SCIE SCOPUS

      Antibody Responses One Year after Mild SARS-CoV-2 Infection

      한글로보기

      https://www.riss.kr/link?id=A107496402

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Understanding the long-term kinetics of antibodies in coronavirus disease 2019 (COVID-19) is essential in interpreting serosurvey data. We investigated the antibody response one year after infection in 52 mildly symptomatic patients with severe acute ...

      Understanding the long-term kinetics of antibodies in coronavirus disease 2019 (COVID-19) is essential in interpreting serosurvey data. We investigated the antibody response one year after infection in 52 mildly symptomatic patients with severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2) infection, using three commercial immunoassays and a surrogate virus neutralization test (sVNT) kit. Anti-N pan-immunoglobulin (Ig), anti-S IgG, and anti-S1 IgG were detected in 43 (82.7%), 44 (84.6%), and 30 (57.7%), respectively. In 49 (94.2%), the antibody could be detected by either anti-N pan-Ig or anti-S IgG assay. In the sVNT, 30 (57.7%) had positive neutralizing activity. Despite waning immunity, SARS-CoV-2 antibodies can be detected up to one year after infection, even in mild COVID-19 patients.

      더보기

      참고문헌 (Reference)

      1 Choe PG, "Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection" 27 (27): 327-329, 2021

      2 Lumley SF, "The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers" 2021

      3 Pyoeng Gyun Choe, "Selecting coronavirus disease 2019 patients with negligible risk of progression: early experience from non-hospital isolation facility in Korea" 대한내과학회 35 (35): 765-770, 2020

      4 Ibarrondo FJ, "Rapid decay of antiSARS-CoV-2 antibodies in persons with mild Covid-19" 383 (383): 1085-1087, 2020

      5 Ripperger TJ, "Orthogonal SARSCoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity" 53 (53): 925.e4-933.e4, 2020

      6 Dan JM, "Immunological memory to SARS-CoV-2assessed for up to 8 months after infection" 371 (371): eabf4063-, 2021

      7 Wu LP, "Duration of antibody responses after severe acute respiratory syndrome" 13 (13): 1562-1564, 2007

      8 Self WH, "Decline in SARSCoV-2 antibodies after mild infection among frontline health care personnel in a multistate hospital network-12 states, April-August 2020" 69 (69): 1762-1766, 2020

      9 Choe PG, "Antibody responses to SARS-CoV-2 at 8 weeks postinfection in asymptomatic patients" 26 (26): 2484-2487, 2020

      10 Choe PG, "Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection" 27 (27): 928-931, 2021

      1 Choe PG, "Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection" 27 (27): 327-329, 2021

      2 Lumley SF, "The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers" 2021

      3 Pyoeng Gyun Choe, "Selecting coronavirus disease 2019 patients with negligible risk of progression: early experience from non-hospital isolation facility in Korea" 대한내과학회 35 (35): 765-770, 2020

      4 Ibarrondo FJ, "Rapid decay of antiSARS-CoV-2 antibodies in persons with mild Covid-19" 383 (383): 1085-1087, 2020

      5 Ripperger TJ, "Orthogonal SARSCoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity" 53 (53): 925.e4-933.e4, 2020

      6 Dan JM, "Immunological memory to SARS-CoV-2assessed for up to 8 months after infection" 371 (371): eabf4063-, 2021

      7 Wu LP, "Duration of antibody responses after severe acute respiratory syndrome" 13 (13): 1562-1564, 2007

      8 Self WH, "Decline in SARSCoV-2 antibodies after mild infection among frontline health care personnel in a multistate hospital network-12 states, April-August 2020" 69 (69): 1762-1766, 2020

      9 Choe PG, "Antibody responses to SARS-CoV-2 at 8 weeks postinfection in asymptomatic patients" 26 (26): 2484-2487, 2020

      10 Choe PG, "Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection" 27 (27): 928-931, 2021

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2011-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2009-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2005-01-01 평가 SCI 등재 (등재유지) KCI등재
      2002-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      1999-07-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 1.48 0.37 1.06
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.85 0.75 0.691 0.11
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼